Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
Aurélien Marabelle, Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoîne Italiano, Tormod Kyrre Guren, Marloes G. J. van Dongen, Kristen Spencer, Giovanni M. Bariani, Paolo A. Ascierto, Armando Santoro, Manisha H. Shah, Jamil Asselah, Syma Iqbal, Shunji Takahashi, Sarina A. Piha‐Paul, Patrick A. Ott, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Jean‐Pierre Delord
Topics & Concepts
MedicinePembrolizumabInternal medicineClinical endpointAnal cancerCohortAdverse effectSurgeryCancerPhases of clinical researchClinical trialOncologyImmunotherapyColorectal and Anal CarcinomasCancer Immunotherapy and BiomarkersIntraperitoneal and Appendiceal Malignancies